Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856643 | 1.00 | HTT (0.56) | HTTTP53AKR1C3MEN1KMT2A | |
| SCHEMBL13765413 | 0.87 | ALDH1A1 (0.50) | HTTTP53AKR1C3MEN1KMT2A | |
| SCHEMBL1898750 | 0.85 | MCL1 (0.46) | HTTTP53AKR1C3MEN1KMT2A | |
| SCHEMBL10570280 | 0.84 | MEN1 (0.49) | HTTTP53AKR1C3MEN1KMT2A | |
| SCHEMBL5466716 | 0.84 | TP53 (0.41) | HTTTP53AKR1C3ALDH1A1CYP3A4 | |
| SCHEMBL2647715 | 0.84 | MEN1 (0.49) | HTTTP53AKR1C3MEN1KMT2A | |
| SCHEMBL5466722 | 0.84 | TP53 (0.41) | HTTTP53AKR1C3ALDH1A1CYP3A4 | |
| SCHEMBL2647713 | 0.84 | MEN1 (0.49) | HTTTP53AKR1C3MEN1KMT2A | |
| SCHEMBL915484 | 0.82 | MEN1 (0.51) | HTTMEN1KMT2AMAPT | |
| SCHEMBL915483 | 0.82 | MEN1 (0.51) | HTTMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948598-B1 | PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT | RANBAXY LAB LTD (IN) | 2013-01-09 | — | — | EP | disclosed |
| US-20100056602-A1 | Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| US-7671216-B2 | Process for preparation of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-02 | — | — | US | disclosed |
| US-20090118520-A1 | PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-07 | — | — | US | disclosed |
| EP-1948598-A1 | PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | disclosed |
| US-20070149605-A1 | Substituted pyrrole derivatives as hmg-coa reductase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-28 | — | — | US | disclosed |
| WO-2007054790-A1 | PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT | RANBAXY LABORATORIES LIMITED (IN) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006110918-A1 | PYRROLE COMPOUNDS AND USES THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1658283-A2 | SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE AS HMG-CO INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2006-05-24 | — | — | EP | disclosed |
| EP-1643988-A1 | SUBSTITUTED PYRROLE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004106299-A2 | SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE AS HMG-CO INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105752-A1 | SUBSTITUTED PYRROLE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-09 | — | — | WO | disclosed |
| US-20040102511-A1 | Substituted pyrrole derivatives | RANBAXY LABORATORIES LIMITED (IN) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056602-A1 | Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors | HMGCR, HMGB2, HMGB3 | HTT 1382/4885TP53 4474/4885AKR1C3 239/4885 |
| US-20070149605-A1 | Substituted pyrrole derivatives as hmg-coa reductase inhibitors | HMGCR, CYP46A1, GRHPR | HTT 1966/4885TP53 3965/4885AKR1C3 42/4885 |
| US-20040102511-A1 | Substituted pyrrole derivatives | HMGCR, PC, CYP46A1 | HTT 1238/4885TP53 4461/4885AKR1C3 207/4885 |
| US-20090118520-A1 | PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT | HPD, HCAR3, ORAI1 | HTT 344/4885TP53 4137/4885AKR1C3 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.